DE60225481D1 - Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung - Google Patents

Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung

Info

Publication number
DE60225481D1
DE60225481D1 DE60225481T DE60225481T DE60225481D1 DE 60225481 D1 DE60225481 D1 DE 60225481D1 DE 60225481 T DE60225481 T DE 60225481T DE 60225481 T DE60225481 T DE 60225481T DE 60225481 D1 DE60225481 D1 DE 60225481D1
Authority
DE
Germany
Prior art keywords
preparation
pharmaceutical formulations
drug release
formulations containing
release pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60225481T
Other languages
English (en)
Other versions
DE60225481T2 (de
Inventor
Kazumichi Yamamoto
Akiko Yamada
Yoshio Hata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26617910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60225481(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60225481D1 publication Critical patent/DE60225481D1/de
Publication of DE60225481T2 publication Critical patent/DE60225481T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
DE60225481T 2001-06-29 2002-06-28 Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung Expired - Lifetime DE60225481T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001199484 2001-06-29
JP2001199484 2001-06-29
JP2001340993 2001-11-06
JP2001340993 2001-11-06

Publications (2)

Publication Number Publication Date
DE60225481D1 true DE60225481D1 (de) 2008-04-17
DE60225481T2 DE60225481T2 (de) 2009-02-26

Family

ID=26617910

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60211464T Expired - Lifetime DE60211464T3 (de) 2001-06-29 2002-06-28 Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
DE60225481T Expired - Lifetime DE60225481T2 (de) 2001-06-29 2002-06-28 Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60211464T Expired - Lifetime DE60211464T3 (de) 2001-06-29 2002-06-28 Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung

Country Status (34)

Country Link
US (4) US7429559B2 (de)
EP (3) EP1949936B1 (de)
JP (5) JP2003206240A (de)
KR (2) KR100961413B1 (de)
CN (3) CN100348265C (de)
AR (2) AR034641A1 (de)
AT (3) ATE509668T1 (de)
AU (2) AU2002311631B2 (de)
BR (1) BRPI0210561B8 (de)
CA (1) CA2455392C (de)
CO (1) CO5540367A2 (de)
CR (1) CR11283A (de)
CY (2) CY1105071T1 (de)
CZ (1) CZ306327B6 (de)
DE (2) DE60211464T3 (de)
DK (2) DK1330293T4 (de)
ES (2) ES2263788T5 (de)
HK (1) HK1056332A1 (de)
HU (1) HU230351B1 (de)
IL (3) IL159059A0 (de)
MX (1) MXPA03011456A (de)
MY (1) MY142066A (de)
NO (1) NO331883B1 (de)
NZ (2) NZ529969A (de)
PE (1) PE20030066A1 (de)
PL (1) PL204903B1 (de)
PT (2) PT1330293E (de)
RU (1) RU2301661C2 (de)
SG (1) SG180015A1 (de)
SI (1) SI1949936T1 (de)
SK (1) SK287577B6 (de)
TW (2) TW200526267A (de)
WO (1) WO2003002092A2 (de)
ZA (1) ZA200309152B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100221A3 (en) * 1998-01-16 2002-11-28 Takeda Pharmaceutical Sustained release compositions, process for producing the same and utilization thereof
AR034641A1 (es) * 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
EP1532985B1 (de) * 2002-06-25 2016-10-12 Takeda Pharmaceutical Company Limited Verfahren zur herstellung einer zusammensetzung mit verzögerter freisetzung
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
ES2427092T3 (es) * 2003-04-10 2013-10-28 Evonik Corporation Un método para la producción de micropartículas a base de emulsión
CA2532302C (en) * 2003-07-15 2016-12-20 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
BRPI0412211A (pt) * 2003-07-23 2006-08-22 Pr Pharmaceuticals Inc composições de liberação controlada
TW200529890A (en) 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
WO2007070563A2 (en) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Stable solid forms of enterostatin
RU2427383C2 (ru) 2006-01-18 2011-08-27 КьюПиЭс, ЭлЭлСи Фармацевтические композиции с повышенной стабильностью
US7858663B1 (en) * 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
MY148370A (en) 2006-12-18 2013-04-15 Takeda Pharmaceutical Sustained-release composition and method for producing the same
US20110319987A1 (en) * 2009-05-20 2011-12-29 Arsenal Medical Medical implant
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
EP3079668A1 (de) 2013-12-09 2016-10-19 Durect Corporation Pharmazeutisch aktive wirkstoffkomplexe, polymerkomplexe und zusammensetzungen und verfahren damit
CN103751851A (zh) * 2014-01-17 2014-04-30 东华大学 一种无机/有机多药物控释复合纳米纤维支架的制备方法
KR101558083B1 (ko) * 2014-04-07 2015-10-07 에스케이케미칼주식회사 약물함유 고분자미립구 제조방법
EP3131532A1 (de) 2014-04-16 2017-02-22 Veyx-Pharma GmbH Veterinärpharmazeutische zusammensetzung und deren verwendung
US10787920B2 (en) 2016-10-12 2020-09-29 General Electric Company Turbine engine inducer assembly
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4258063A (en) 1978-06-23 1981-03-24 Henkel Corporation Self-emulsifying cosmetic base
US4249531A (en) 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4479911A (en) 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4539981A (en) 1982-11-08 1985-09-10 Johnson & Johnson Products, Inc. Absorbable bone fixation device
FR2537980B1 (fr) 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1236641A (en) 1984-07-06 1988-05-10 Motoaki Tanaka Copolymer of lactic acid and glycolic acid and method for producing same
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
EP0190833B1 (de) 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung von Mikrokapseln
JP2551756B2 (ja) † 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
CA2040141C (en) * 1990-04-13 2002-05-14 Minoru Yamada Biodegradable high-molecular polymers, production and use therof
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
US5353086A (en) * 1993-05-03 1994-10-04 Eastman Kodak Company Textured surface with canted channels for an automatic tray processor
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
CA2143044C (en) 1994-02-21 2005-04-12 Yasutaka Igari Matrix for sustained-release preparation
US5763513A (en) 1994-05-19 1998-06-09 Mitsui Toatsu Chemicals, Inc. L-lactic acid polymer composition, molded product and film
JPH08259460A (ja) * 1995-01-23 1996-10-08 Takeda Chem Ind Ltd 徐放性製剤の製造法
JP3902272B2 (ja) * 1995-09-04 2007-04-04 武田薬品工業株式会社 徐放性製剤の製造法
US5922662A (en) * 1996-08-07 1999-07-13 Colgate Palmolive Company High foaming nonionic surfactant based liquid detergent
EP0839525B1 (de) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter Freisetzung
AU5678398A (en) 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
JPH10273447A (ja) * 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
HUP0100221A3 (en) 1998-01-16 2002-11-28 Takeda Pharmaceutical Sustained release compositions, process for producing the same and utilization thereof
US6114495A (en) 1998-04-01 2000-09-05 Cargill Incorporated Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
WO2000035990A1 (fr) * 1998-12-15 2000-06-22 Takeda Chemical Industries, Ltd. Procede de production d'un polymere
JP2000238051A (ja) † 1999-02-23 2000-09-05 Kansei Corp 表皮シートの発泡成形型へのセッティング方法
WO2001005380A1 (fr) * 1999-07-15 2001-01-25 Takeda Chemical Industries, Ltd. Compositions a liberation lente, techniques de production et methodes d'utilisation
JP2001081043A (ja) * 1999-07-15 2001-03-27 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
JP3837607B2 (ja) † 2000-05-29 2006-10-25 Ｔｃｍ株式会社 マスト用溶接位置決め治具
PT1693054T (pt) 2000-08-07 2016-07-07 Takeda Pharmaceuticals Co Polímero de ácido láctico e processo para a sua produção
WO2002043766A1 (fr) * 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Compositions medicinales et leur procede de preparation
AU2002221139A1 (en) * 2000-12-15 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
AR034641A1 (es) * 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla

Also Published As

Publication number Publication date
CA2455392C (en) 2011-11-22
ATE509668T1 (de) 2011-06-15
DK1330293T4 (da) 2011-01-10
TWI332407B (en) 2010-11-01
ES2263788T3 (es) 2006-12-16
JP2010189427A (ja) 2010-09-02
MXPA03011456A (es) 2004-07-01
CR11283A (es) 2010-05-31
SK15602003A3 (sk) 2004-06-08
SG180015A1 (en) 2012-05-30
ZA200309152B (en) 2005-01-26
US8815801B2 (en) 2014-08-26
JP4819172B2 (ja) 2011-11-24
WO2003002092A3 (en) 2003-04-10
DE60211464T3 (de) 2011-03-17
DE60211464T2 (de) 2006-09-07
DE60225481T2 (de) 2009-02-26
AR034641A1 (es) 2004-03-03
ATE387937T1 (de) 2008-03-15
RU2301661C2 (ru) 2007-06-27
US20090005318A1 (en) 2009-01-01
NO20035738D0 (no) 2003-12-19
WO2003002092A2 (en) 2003-01-09
CN1724066A (zh) 2006-01-25
AU2006246508B2 (en) 2008-09-04
JP2004238400A (ja) 2004-08-26
BRPI0210561B1 (pt) 2018-08-14
CA2455392A1 (en) 2003-01-09
AU2002311631B2 (en) 2007-02-08
CY1111708T1 (el) 2015-10-07
US8067030B2 (en) 2011-11-29
EP1491236B1 (de) 2008-03-05
PT1949936E (pt) 2011-07-12
EP1491236A1 (de) 2004-12-29
RU2004102507A (ru) 2005-03-10
AR098261A2 (es) 2016-05-18
CN100577206C (zh) 2010-01-06
DK1949936T3 (da) 2011-08-15
KR20090020708A (ko) 2009-02-26
ES2263788T5 (es) 2011-02-22
PT1330293E (pt) 2006-08-31
BR0210561A (pt) 2004-06-22
BRPI0210561B8 (pt) 2021-05-25
JP2009167203A (ja) 2009-07-30
SI1949936T1 (sl) 2011-08-31
EP1330293B2 (de) 2010-10-27
SK287577B6 (sk) 2011-03-04
PE20030066A1 (es) 2003-03-20
EP1949936B1 (de) 2011-05-18
US8246987B2 (en) 2012-08-21
AU2006246508A1 (en) 2006-12-21
CN1292796C (zh) 2007-01-03
JP2010189428A (ja) 2010-09-02
HU230351B1 (hu) 2016-02-29
KR100916173B1 (ko) 2009-09-08
NZ529969A (en) 2005-10-28
KR100961413B1 (ko) 2010-06-09
CO5540367A2 (es) 2005-07-29
CY1105071T1 (el) 2010-03-03
CN100348265C (zh) 2007-11-14
IL186782A0 (en) 2008-02-09
CN1868458A (zh) 2006-11-29
TW200526267A (en) 2005-08-16
NO20035738L (no) 2004-02-27
EP1330293A2 (de) 2003-07-30
ATE326264T1 (de) 2006-06-15
HUP0400378A3 (en) 2010-01-28
CN1535168A (zh) 2004-10-06
PL367518A1 (en) 2005-02-21
EP1330293B1 (de) 2006-05-17
MY142066A (en) 2010-08-30
IL159059A0 (en) 2004-05-12
HUP0400378A2 (hu) 2004-12-28
ES2366677T3 (es) 2011-10-24
US7429559B2 (en) 2008-09-30
KR20040018402A (ko) 2004-03-03
EP1949936A2 (de) 2008-07-30
PL204903B1 (pl) 2010-02-26
DE60211464D1 (de) 2006-06-22
US20110166084A1 (en) 2011-07-07
US20030134800A1 (en) 2003-07-17
CZ306327B6 (cs) 2016-12-07
EP1949936A3 (de) 2008-10-08
NO331883B1 (no) 2012-04-23
NZ541884A (en) 2007-01-26
US20120283187A1 (en) 2012-11-08
CZ20033493A3 (cs) 2004-08-18
DK1330293T3 (da) 2006-09-11
HK1056332A1 (en) 2004-02-13
IL159059A (en) 2011-06-30
JP4819173B2 (ja) 2011-11-24
JP2003206240A (ja) 2003-07-22

Similar Documents

Publication Publication Date Title
DE60225481D1 (de) Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung
ES2628883T3 (es) Procedimiento para la preparación de un laminado extruido en estado fundido en caliente
DE60232147D1 (de) Pharmazeutische zubereitung mit verzögerter wirkstoff-freisetzung enthaltend milchsäure-glycolsäure copolymer, und verfahren zu deren herstellung
DE50212302D1 (de) 17alpha-alkyl-17beta-oxy-estratriene und zwischenprodukte zu deren herstellung, verwendung der 17alpha-alkyl-17beta-oxy-estratriene zur herstellung von arzneimitteln sowie pharmazeutische präparate
ATE277594T1 (de) Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
DE60142890D1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
DE60100186D1 (de) Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung
ATE233752T1 (de) Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
EP1483277A4 (de) Konjugate biologisch aktiver verbindungen, verfahren zu deren herstellung und anwendung, formulierung und pharmazeutische anwendungen davon
DE60212475D1 (de) Pharmazeutische Tablette und eine Verfahren zu deren Herstellung
HRP20040849A2 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
DE60313359D1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
BG108516A (en) Pharmaceutical formulation
DE60301570D1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ATA59499A (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
DE60042972D1 (de) Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung
WO2001013898A3 (en) Pharmaceutical formulations with different release times
DE60203178D1 (de) Pharmazeutische formulierung mit überdecktem geschmack und verfahren zu ihrer herstellung
ATE303137T1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
DE60033519D1 (de) Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen
ATE410149T1 (de) Komprimierte, orale pharmazeutische dosierungsform mit enterischer beschichtung, die eine säurelabile benzimidazolverbindung enthält
ATE245974T1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
DE60109279D1 (de) Pharmazeutische zusammensetzungen mit oligosacchariden und deren herstellung
DE60003662D1 (de) Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition